Table 2.
Results of gene array studies: selected genes with their name, gene bank accession number, chromosome localization and signal log ratio relative value, are shown
| Biological pathway | Gene Bank accession number | Chromosome location | Patient #1 | Patient #2 | ||
|---|---|---|---|---|---|---|
| ≥ 2-fold changes | ≥ 2-fold changes | |||||
| FN | NN | FN | NN | |||
| Apoptosis | ||||||
| TNF-related apoptosis inducing ligand (TRAIL) | U37518 | 3q26.31 | − 1.3 | |||
| Tumor necrosis factor receptor type 1 (TNFR1) | X55313 | 12p13.31 | 1.0 | |||
| Bcl2 | M14745 | 18q21.33 | − 1.3 | |||
| BH3 interacting domain death agonist (BID) | AF042083 | 22q11.21 | 2.7 | |||
| Cytochrome c (Cytc) | BC005299 | 7p15.3 | 1.2 | |||
| IAP 1 | AF070674 | 11q22.1 | − 1.8 | − 2.0 | ||
| c-Jun | J04111 | 1p32.2 | − 1.9 | − 1.8 | ||
| TRAF2 | U12597 | 9q34.3 | 1.6 | |||
| Blood clotting cascade | ||||||
| von Willebrand factor | M25828 | 12p13.31 | 1.6 | |||
| Coagulation factor V | M14335 | 1q24.2 | 1.3 | |||
| Pro-urokinase plasminogen activator | M15476 | 10q22.2 | 1.6 | |||
| Calcium channels | ||||||
| Inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) | D26070 | 3p26.1 | − 2.0 | 2.1 | ||
| Ryanodine receptor 1 (RYR1) | U48508 | 19q13.13 | 2.4 | |||
| Cell cycle | ||||||
| Cyclin-dependent kinase inhibitor 1 (Melanoma differentiation associated protein 6) (Cip1) | U09579 | 6p21.31 | 1.3 | 1.3 | 1.6 | 1.0 |
| Transforming growth factor beta 1 precursor (TGF-β1) | BC000125 | 19q13.2 | 1.4 | |||
| Cyclin D3 (CycD3) | M92287 | 6p21.1 | 1.3 | |||
| Cyclin D2 (CycD2) | D13639 | 12p13.32 | 1.0 | |||
| Histone deacetylase 4 (HDAC4) | AB006626 | 2q37.3 | − 1.0 | |||
| P107 (RBL1) | AL136172 | 20q11.23 | − 1.1 | |||
| SMAD4 (DPC4) | AF045438 | 18q21.1 | 1.1 | |||
| RB1 | M27845 | 13q14.2 | 1.0 | |||
| PTTG3 | AF095289 | 5q33.3 | 1.0 | |||
| Classical complement activation | ||||||
| Complement component 1, β-chain (C1q β) | X03084 | 1p36.12 | 1.4 | 1.1 | ||
| Decay-accelerating factor (DAF) | M31516 | 1q32.2 | 1.3 | |||
| Complement subcomponent C1s, α- and β-chains (C1s) | M18767 | 12p13.31 | − 2.5 | − 2.0 | − 1.4 | − 1.1 |
| Complement component C4B (C4) | K02403 | 6p21.33 | 1.4 | |||
| Complement protein component C7 | J03507 | 5p13.1 | − 2.5 | − 2.7 | − 2.6 | − 2.7 |
| Complement component C3, α- and β-subunits (C3) | K02765 | 19p13.3 | − 2.5 | − 2.5 | − 3.1 | |
| Cytoplasmic ribosomal proteins | ||||||
| Ribosomal protein L5 | U14966 | 1p22.1 | − 1.1 | |||
| Ribosomal protein S8 | X67247 | 1p34.1 | − 1.1 | |||
| Ribosomal protein S9 | U14971 | 19p13.42 | − 1.0 | |||
| Ribosomal protein S10 | U14972 | 6p21.31 | − 1.1 | |||
| Cytoplasmic tRNA synthetases | ||||||
| Tryptophanyl-tRNA synthetase (TrpRS) | M61715 | 14q32.2 | 1.5 | 1.3 | 1.4 | |
| Eicosanoid synthesis | ||||||
| Prostacyclin (prostaglandin I2) synthase | AL118525 | 20q13.13 | − 1.6 | − 1.6 | ||
| Prostaglandin D2 synthase | BC005939 | 9q34.3 | 1.7 | − 2.7 | − 1.0 | |
| Phospholipase A2, membrane associated precursor | M22430 | 1p36.13 | − 1.1 | |||
| Arachidonate 5-lipoxygenase | J03600 | 10q11.21 | 2.2 | − 2.6 | ||
| Electron transport chain | ||||||
| Cytochrome bc-1 complex core protein II | J04973 | 16p12.2 | − 1.0 | |||
| Uncoupling protein 2 (UCP2) | U94592 | 11q13.4 | 1.2 | 1.4 | ||
| Cytochrome c | BC005299 | 7p15.3 | 1.2 | |||
| Cytochrome c oxidase subunit VIIb (COX7b) | Z14244 | Xq21.1 | 1.1 | |||
| Cytochrome c oxidase copper chaperone (COX17) | L77701 | 3q13.33 | 1.0 | 1.1 | ||
| NADH-ubiquinone oxidoreductase AGGG subunit | AF050639 | 7q34 | 1.1 | |||
| ATP synthase lipid-binding protein | AL080089 | 17q21.32 | 1.2 | |||
| Fatty acid degradation | ||||||
| Long-chain acyl-coenzyme A synthetase (FACL1) | L09229 | 4q35.1 | − 1.0 | − 1.1 | ||
| Carnitine palmitoyltransferase I, mithocondrial protein | U62733 | 22q13.33 | 1.3 | |||
| Long-chain fatty acid coA ligase 2 | D10040 | 4q35.1 | 1.2 | |||
| Gap junction proteins-connexins | ||||||
| Connexin 43 | X52947 | 6q22.31 | − 1.0 | |||
| Connexin 37 | M96789 | 1p35.1 | 1.1 | |||
| Connexin 31 | AF099730 | 1p34 | 1.3 | |||
| Glycolisis and gluconeogenesis | ||||||
| Phosphoglycerate mutase | J04173 | 10q24.1 | 1.2 | |||
| G-protein signaling | ||||||
| G protein β 5 subunit (Gβ5) | AF017656 | 15q21.2 | − 1.7 | − 1.4 | ||
| cAMP-specific phosphodiesterase | L20971 | 1p31.2 | − 2.4 | |||
| cAMP-dependent protein kinase subunit RII-β (PRKARII β) | M31158 | 7q22.3 | − 1.2 | − 2.3 | ||
| Inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) | D26070 | 3p26.1 | − 2.0 | 2.1 | ||
| G-protein alpha subunit 14 (Gα14) | AF105201 | 9q21.2 | − 1.7 | |||
| Protein kinase C β 2 (PKC β 2) | M18255 | 16p12.2 | − 3.5 | − 2.1 | ||
| GPCRs class A rhodopsin-like | ||||||
| Bradykinin receptor B2 (BDKRB2) | AF378542 | 14q32.2 | 1.5 | 2.7 | ||
| Thrombin receptor (F2R) | M62424 | 5q13.3 | 1.2 | 1.7 | ||
| Chemokine receptor-4 (CXCR4) | AJ224869 | 2q21.3 | 1.1 | − 1.2 | − 2.0 | |
| Encephalopsin (opsin3, panopsin) | AF140242 | 1q43 | − 1.0 | |||
| G protein-coupled receptor V28 (chemokine receptor-1) | U20350 | 3p22.2 | 1.3 | |||
| Adenosine A1-receptor (ADORA1) | L22214 | 1q32.1 | 2.3 | |||
| C5a anaphylatoxin receptor (C5R1) | M62505 | 19q13.32 | 1.8 | |||
| Monocyte chemoattractant protein 1 receptor (MCP-1 R) | D29984 | 3p21.31 | − 1.8 | |||
| Human Epstein-Barr virus-induced G-protein coupled receptor (EBI 1, CCR 7) | L31582 | 17q21.2 | − 1.7 | − 2.1 | ||
| Neuropeptide Y receptor Y1 (NPYY1) | L07614 | 4q32.2 | − 1.5 | |||
| CB1 cannabinoid receptor (CNR1) | U73304 | 6q15 | − 1.2 | |||
| Apelin receptor | U03642 | 11q12.1 | 1.8 | |||
| Q9BXA0 | AF348491 | 2q21.3 | − 1.4 | − 1.7 | ||
| GPCRs class B secretin-like | ||||||
| Lectomedin-1 γ | AF104939 | 1p31.1 | − 1.0 | − 1.4 | ||
| ETL protein | AF192403 | 1p31.1 | 1.0 | 1.3 | ||
| GPCRs class C metabotropic glutamate | ||||||
| Putative G protein-coupled receptor (RAIG1) | AF095448 | 12p13.2 | 1.2 | 1.6 | ||
| GABA-B-R2 | AF099033 | 9q22.33 | 2.6 | |||
| GPCR 5B protein | AC004131 | 16p12.3 | 1.1 | |||
| GPCRs others | ||||||
| Duffy blood group antigen (FY) | U01839 | 1q23.1 | − 1.6 | − 1.6 | ||
| G13 signaling | ||||||
| GDP-dissociation inhibitor protein | L20688 | 12p12.3 | 1.4 | |||
| Phosphoinositide 3-kinase PI3-K D | Y10055 | 1p36.22 | − 1.8 | |||
| IQGAP2 | Q13576 | 5q13.3 | 1.1 | |||
| Inflammatory response | ||||||
| Cellular fibronectin precursor | X02761 | 2q35 | 3.4 | 1.2 | 2.6 | |
| Laminin gamma2 chain | U31201 | 1q25.3 | 1.1 | |||
| Tumor necrosis factor receptor type 1 | X55313 | 12p13.31 | 1.0 | |||
| Lymphocyte-specific protein-tyrosine kinase (LCK) | M21510 | 1p35.2 | − 1.5 | − 2.1 | ||
| Interleukin 2 receptor γ chain | D11086 | Xq13.1 | − 1.0 | − 1.2 | ||
| MAPK cascade | ||||||
| GTPase-activating protein ras p21 | M23379 | 5q14.3 | 1.0 | |||
| c-Jun | J04111 | 1p32.2 | − 1.9 | − 1.8 | ||
| Matrix metalloproteinases | ||||||
| Tissue inhibitor of metalloproteinase-3 (TIMP3) | U67195 | 22q12.3 | 1.2 | |||
| Collagenase type IV (MMP-2) | M58552 | 16q12.2 | − 1.4 | |||
| Tissue inhibitor of metalloproteinases-1 (TIMP1) | X03124 | Xp11.3 | 2.0 | |||
| Matrix metalloproteinase 9 (MMP-9) | BC006093 | 20q13.12 | − 1.6 | |||
| Nuclear receptors | ||||||
| β-glucocorticoid receptor | X03348 | 5q31.3 | − 1.1 | |||
| Apolipoprotein AI regulatory protein | M64497 | 15q26.2 | − 1.0 | |||
| Retinoid X receptor-γ | U38480 | 1q23.3 | 2.6 | |||
| Nucleotide metabolism | ||||||
| NAD-dependent methylene tetrahydrofolate dehydrogenase cyclohydrolase (CH2H4 Folate DH) | X16396 | 2p13.1 | − 1.0 | |||
| Peptide GPCRs | ||||||
| ATPaseII | AB013452 | 4p13 | − 2.3 | |||
| Bradykinin receptor B2 (BDKRB2) | AF378542 | 14q32.2 | 1.5 | 2.7 | ||
| Monocyte chemoattractant protein 1 receptor (MCP-1 R) | D29984 | 3p21.31 | − 1.8 | |||
| Human Epstein-Barr virus-induced G-protein coupled receptor (EBI 1, CCR 7) | L31582 | 17q21.2 | − 1.7 | − 2.1 | ||
| Chemokine receptor-4 (CXCR4) | AJ224869 | 2q21.3 | 1.1 | − 1.2 | − 2.0 | |
| Duffy blood group antigen (FY) | U01839 | 1q23.1 | − 1.6 | − 1.6 | ||
| C5a anaphylatoxin receptor (C5R1) | M62505 | 19q13.32 | 1.8 | |||
| Neurokinin 1 receptor (NKIR) | M76675 | 2p12 | − 1.9 | |||
| Neuropeptide Y receptor Y1 (NPYY1) | L07614 | 4q32.2 | − 1.5 | |||
| G protein-coupled receptor V28 (chemokine receptor-1) | U20350 | 3p22.2 | 1.3 | |||
| Proteasome degradation | ||||||
| Histone H2A.x | X14850 | 11q23.3 | 1.2 | |||
| Proteasome subunit LMP7 | U17496 | 6p21.32 | 1.3 | − 1.0 | ||
| Small ligand GPCRs | ||||||
| CB1 cannabinoid receptor (CNR1) | U73304 | 6q15 | − 1.2 | |||
| TGF B signalling | ||||||
| Transforming growth factor beta 1 precursor (TGF-β1) | BC000125 | 19q13.2 | 1.4 | |||
| Transcription factor ISGF-3 (STAT1) | M97935 | 2q32.2 | 1.0 | |||
| Mad-related protein (SMAD1) | U54826 | 4q31.21 | − 1.2 | |||
| KIAA0569 protein (Sip1) | AB011141 | 2q22.3 | − 1.3 | |||
| TGF-β type III receptor | L07594 | 1p32.2 | − 1.2 | |||
| SMAD4 (DPC4) | AF045438 | 18q21.1 | 1.1 | |||
| c-Jun | J04111 | 1p32.2 | − 1.9 | − 1.8 | ||
| Thrombospondin | J04835 | 15q15.1 | 2.2 | |||
| Lymphoid enhancer binding factor 1 (LEF-1) | AF198532 | 4q25 | 1.9 | |||
| Translation factors | ||||||
| Eukaryotic translation initiation factor 2 α kinase 3 | AF110146 | 2p11.2 | 1.7 | |||
| Eukaryotic translation initiation factor eIF-2 α subunit | L19161 | Xp22.11 | − 1.3 | |||
| Wnt signaling | ||||||
| Frizzled 1 | AF072872 | 7q21.13 | − 1.2 | − 1.0 | ||
| Proto-oncogene (Wnt-5a) | L20861 | 3p14.3 | 1.0 | − 1.4 | ||
| Cyclin D1 | BC000076 | 11q13.3 | 1.5 | 1.4 | 1.4 | |
| Cyclin D2 | D13639 | 12p13.32 | 1.0 | |||
| Cyclin D3 | M92287 | 6p21.1 | 1.3 | |||
| Urokinase-type plasminogen activator precursor | M15476 | 10q22.2 | 1.6 | |||
| Frizzled 7 | AB017365 | 2q33.1 | − 1.4 | |||
| Frizzled 10 | AB027464 | 12q24.33 | − 1.0 | |||
| c-Jun | J04111 | 1p32.2 | − 1.9 | − 1.8 | ||
| Protein kinase C β 2 (PKC β 2) | M18255 | 16p12.2 | − 3.5 | − 2.1 | ||
| Frizzled 2 | AB017364 | 17q21.31 | − 1.0 | |||
Several genes appear more than one time because associated with different biological pathways